An Phase III Study, Multicenter ，Randomized Controlled Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Conditions: Bladder Cancer Interventions: Drug: Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib; Drug: Tislelizumab, Cisplatin, Gemcitabine Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials